News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx Presents Positive Phase 2 Clinical Data for Traficet-EN™ in Crohn's Disease at the Digestive Disease Week 2007 Conference
Clear Anti-Inflammatory Activity Demonstrated Among Patients with Active Disease
View HTML
Toggle Summary ChemoCentryx's Traficet-EN™ Phase 2 Data in Crohn's Disease Accepted for Oral Presentation and Highlighted in "Best of UEGW" Session at DDW 2007
ChemoCentryx's Traficet-EN™ Phase 2 Data in Crohn's Disease Accepted for Oral Presentation and Highlighted in "Best of UEGW" Session at DDW 2007 Mountain View, CA - May 17, 2007 — ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing
View HTML
Toggle Summary ChemoCentryx Appoints Juan Jaen, Ph.D., Senior Vice President, Drug Discovery
ChemoCentryx Appoints Juan Jaen, Ph.D., Senior Vice President, Drug Discovery Mountain View, CA - January 4, 2007 — ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine
View HTML
Toggle Summary ChemoCentryx Presents Clinical and Preclinical Data on Traficet-EN® in Inflammatory Bowel Disease (IBD)
Clinical Analysis Shows that Traficet-EN Reduces Inflammation Associated with IBD
View HTML
Toggle Summary ChemoCentryx Reports Promising Clinical Activity for Traficet-EN™ from Phase 2 Trial for the Treatment of Crohn's Disease
Phase 2 Results Used in Design of Ongoing 400+ Patient PROTECT-1 Clinical Trial
View HTML
Toggle Summary ChemoCentryx Completes Series C Financing
ChemoCentryx Completes Series C Financing Mountain View, CA, USA; August 24, 2006 — ChemoCentryx, Inc. today announced that it has recently completed a Series C financing in June 2006 with participating investors including Jennison Associates, HBM BioVentures, Orbimed Advisors, Techne Corporation,
View HTML
Toggle Summary GlaxoSmithKline and ChemoCentryx Enter Into Drug Discovery and Development Alliance in Inflammatory Disorders
GlaxoSmithKline and ChemoCentryx Enter Into Drug Discovery and Development Alliance in Inflammatory Disorders London, UK, Philadelphia, PA and Mountain View, CA, USA; August 24, 2006 — GlaxoSmithKline (NYSE: GSK) and ChemoCentryx, Inc. today announced a worldwide multi-target strategic alliance to
View HTML
Toggle Summary ChemoCentryx Names Regina E. Herzlinger to the Company's Board of Directors
ChemoCentryx Names Regina E. Herzlinger to the Company's Board of Directors Mountain View, CA; February 7, 2006 — ChemoCentryx, Inc., a clinical-stage, biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system,
View HTML
Toggle Summary ChemoCentryx Announces Key Senior Management Team Additions
Susan M. Kanaya Appointed Chief Financial Officer
View HTML
Toggle Summary ChemoCentryx to Initiate Clinical Studies of CCR2 Antagonist CCX915
Investigational New Drug Application on File — Studies to Commence by Year End
View HTML